HCW Biologics reports positive Phase 1 data for IL-2 immunotherapy HCW9302 in alopecia areata

HCW Biologics announced positive preliminary results from its Phase 1 clinical trial of HCW9302, with all three patients in the second dose cohort showing ≥25% improvement in alopecia severity scores and no dose-limiting toxicities reported. The well-tolerated results support the company's goal to establish a recommended Phase 2 dose by end of 2026, potentially advancing its pipeline for autoimmune diseases.